Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 3
2020 1
2021 6
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H, Ilaria R, O'Connell B, Peng J, Peng G, Zizlsperger N, Tolcher A, Wolchok JD. Hong DS, et al. Clin Cancer Res. 2023 Jun 13;29(12):2210-2219. doi: 10.1158/1078-0432.CCR-22-3313. Clin Cancer Res. 2023. PMID: 37000164 Free PMC article. Clinical Trial.
A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity.
Abrego J, Sanford-Crane H, Oon C, Xiao X, Betts CB, Sun D, Nagarajan S, Diaz L, Sandborg H, Bhattacharyya S, Xia Z, Coussens LM, Tontonoz P, Sherman MH. Abrego J, et al. Cancer Discov. 2022 Oct 5;12(10):2414-2433. doi: 10.1158/2159-8290.CD-22-0661. Cancer Discov. 2022. PMID: 35894778 Free PMC article.
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Taylor MH, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel P, Munugalavadla V, Tao L, Adkins D, Goldschmidt JH, Cohen EEW, Coussens LM. Taylor MH, et al. Clin Cancer Res. 2022 Mar 1;28(5):903-914. doi: 10.1158/1078-0432.CCR-21-2547. Clin Cancer Res. 2022. PMID: 34862248 Free PMC article. Clinical Trial.
MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging.
Schapiro D, Sokolov A, Yapp C, Chen YA, Muhlich JL, Hess J, Creason AL, Nirmal AJ, Baker GJ, Nariya MK, Lin JR, Maliga Z, Jacobson CA, Hodgman MW, Ruokonen J, Farhi SL, Abbondanza D, McKinley ET, Persson D, Betts C, Sivagnanam S, Regev A, Goecks J, Coffey RJ, Coussens LM, Santagata S, Sorger PK. Schapiro D, et al. Nat Methods. 2022 Mar;19(3):311-315. doi: 10.1038/s41592-021-01308-y. Epub 2021 Nov 25. Nat Methods. 2022. PMID: 34824477 Free PMC article.
Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.
Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, Chiorean EG, O'Hara MH, Liudahl SM, Newcomb C, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. Byrne KT, et al. Clin Cancer Res. 2021 Aug 15;27(16):4574-4586. doi: 10.1158/1078-0432.CCR-21-1047. Epub 2021 Jun 10. Clin Cancer Res. 2021. PMID: 34112709 Free PMC article. Clinical Trial.
PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
Li J, Kaneda MM, Ma J, Li M, Shepard RM, Patel K, Koga T, Sarver A, Furnari F, Xu B, Dhawan S, Ning J, Zhu H, Wu A, You G, Jiang T, Venteicher AS, Rich JN, Glass CK, Varner JA, Chen CC. Li J, et al. Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):e2009290118. doi: 10.1073/pnas.2009290118. Proc Natl Acad Sci U S A. 2021. PMID: 33846242 Free PMC article.
16 results